Lupin launches generic HIV drug

Federal court rules that Lupin's product doesn't infringe on ViiV Healthcare's patent

BALTIMORE — Lupin has launched a generic drug for treating HIV, following its victory in a patent-infringement suit in federal court, the Indian drug maker said Wednesday.

Lupin's U.S. subsidiary launched its generic version of ViiV Healthcare's Trizivir (abacavir sulfate; lamivudine; zidovudine) tablets in the 300-mg/150-mg/300-mg strength. The launch follows a ruling by the U.S. District Court for the District of Delaware that the drug did not infringe on Viiv's patent.

Trizivir had sales of about $111.6 million during the 12-month period that ended in September, according to IMS Health.


Login or Register to post a comment.